delayed action preparations

Summary

Summary: Dosage forms of a drug that act over a period of time by controlled-release processes or technology.

Top Publications

  1. ncbi Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:181-9. 2010
  2. ncbi Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial
    Frank Buttgereit
    Department of Rheumatology and Clinical Immunology, Charite University Medicine, Berlin, Germany
    Lancet 371:205-14. 2008
  3. ncbi Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study
    Fabrizio Stocchi
    Institute of Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy
    Curr Med Res Opin 24:2883-95. 2008
  4. ncbi A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder
    Laurence L Greenhill
    New York State Psychiatric Institute, New York, New York 10032, USA
    Pediatrics 109:E39. 2002
  5. ncbi Mucoadhesive polymeric platforms for controlled drug delivery
    Gavin P Andrews
    School of Pharmacy, The Queen s University of Belfast, Belfast, Ireland
    Eur J Pharm Biopharm 71:505-18. 2009
  6. ncbi Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies
    John M Kane
    Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Psychiatry 64:34-40. 2003
  7. ncbi Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
  8. ncbi Melatonin reduces night blood pressure in patients with nocturnal hypertension
    Ehud Grossman
    Department of Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Tel Hashomer, Affiliated with Sackler School of Medicine, Tel Aviv University, Israel
    Am J Med 119:898-902. 2006
  9. ncbi A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats
    Ben J Boyd
    Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
    Int J Pharm 340:52-60. 2007
  10. ncbi The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome
    M Thoenes
    Institut fur Klinische Pharmakologie, Technische Universitat Dresden, Dresden, Germany
    Int J Clin Pract 61:1942-8. 2007

Research Grants

  1. PILOT EXPLORATIONS OF ZINC EFFECTS IN ADHD
    L Arnold; Fiscal Year: 2007
  2. Dopamine Transporter Binding by PET in Adult ADHD
    Thomas Spencer; Fiscal Year: 2007
  3. AN ECOGENETIC STUDY OF ADHD
    Stephen Faraone; Fiscal Year: 2003
  4. TESTING THE VALIDITY OF ADULT ATTENTION DEFICIT DISORDER
    Stephen Faraone; Fiscal Year: 2002
  5. CONTROLLED STUDY OF METHYLPHENIDATE IN ADULTS WITH ADHD
    Thomas Spencer; Fiscal Year: 2002
  6. Validating Novel Familial Phenotypes of Drug Abuse
    Stephen Faraone; Fiscal Year: 2007
  7. Analysis of an ADHD Whole Genome Association Scan
    Stephen Faraone; Fiscal Year: 2007
  8. International Multi-Center ADHD Genetics Project
    Stephen Faraone; Fiscal Year: 2007
  9. 2/5-The Psychiatric GWAS Consortium: Integrated & Coordinated GWAS Meta-Analyses
    Stephen Faraone; Fiscal Year: 2008
  10. Searching for ADHD Susceptibility Genes
    Stephen V Faraone; Fiscal Year: 2010

Detail Information

Publications262 found, 100 shown here

  1. ncbi Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:181-9. 2010
    ..The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophrenia...
  2. ncbi Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial
    Frank Buttgereit
    Department of Rheumatology and Clinical Immunology, Charite University Medicine, Berlin, Germany
    Lancet 371:205-14. 2008
    ..We aimed to assess the efficacy and safety of a new modified-release prednisone tablet compared with immediate-release prednisone in patients with this disease...
  3. ncbi Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study
    Fabrizio Stocchi
    Institute of Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy
    Curr Med Res Opin 24:2883-95. 2008
    ..This study compares once-daily ropinirole 24-h prolonged release and three-times-daily ropinirole immediate release in patients with early Parkinson's disease...
  4. ncbi A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder
    Laurence L Greenhill
    New York State Psychiatric Institute, New York, New York 10032, USA
    Pediatrics 109:E39. 2002
    ..To compare the efficacy, safety, and tolerability of once-daily administration of modified-release methylphenidate (MPH MR) with placebo in children with attention-deficit/hyperactivity disorder (ADHD)...
  5. ncbi Mucoadhesive polymeric platforms for controlled drug delivery
    Gavin P Andrews
    School of Pharmacy, The Queen s University of Belfast, Belfast, Ireland
    Eur J Pharm Biopharm 71:505-18. 2009
    ..Evolution of such mucoadhesive formulations has transgressed from first-generation charged hydrophilic polymer networks to more specific second-generation systems based on lectin, thiol and various other adhesive functional groups...
  6. ncbi Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies
    John M Kane
    Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Psychiatry 64:34-40. 2003
    ....
  7. ncbi Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
    ..The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia...
  8. ncbi Melatonin reduces night blood pressure in patients with nocturnal hypertension
    Ehud Grossman
    Department of Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Tel Hashomer, Affiliated with Sackler School of Medicine, Tel Aviv University, Israel
    Am J Med 119:898-902. 2006
    ..We therefore studied the potency of melatonin to reduce nighttime blood pressure (BP) in treated hypertensive patients with nocturnal hypertension...
  9. ncbi A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats
    Ben J Boyd
    Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
    Int J Pharm 340:52-60. 2007
    ..The results indicate that lipids that form liquid crystalline structures in excess water, may have application as an oral sustained release delivery system, providing they are not digested rapidly on administration...
  10. ncbi The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome
    M Thoenes
    Institut fur Klinische Pharmakologie, Technische Universitat Dresden, Dresden, Germany
    Int J Clin Pract 61:1942-8. 2007
    ..We studied the effects of niacin on carotid intimal media thickness (IMT), brachial artery reactivity as well as markers of inflammation and the metabolic profile of patients with metabolic syndrome...
  11. ncbi PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 163:387-95. 2006
    ....
  12. ncbi Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Innsbruck University Clinics, Anichstrasse 35, 6020 Innsbruck, Austria
    J Clin Psychiatry 64:1250-7. 2003
    ..The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia...
  13. ncbi Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique
    Shigeyuki Takada
    Drug Formulation Research Laboratories, Takeda Chemical Industries, Ltd, 2 17 85, Juso honmachi, Yodogawa ku, Osaka 532 8686, Japan
    J Control Release 88:229-42. 2003
    ....
  14. ncbi Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 15:257-63. 2007
    ..This review will discuss the impact of adherence to prescribed therapies for CVD, outline common barriers to adherence, and demonstrate the value of once-daily dosing regimens for improved patient adherence...
  15. pmc Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
    Holland C Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    BMC Psychiatry 10:43. 2010
    ..During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI...
  16. ncbi The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia
    Remy Luthringer
    Forenap Pharma, Rouffach, France
    Int Clin Psychopharmacol 24:239-49. 2009
    ..Daytime psychomotor performance was not impaired and was consistently better with PRM compared with placebo. PRM was well tolerated with no evidence of rebound effects...
  17. ncbi Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems
    Steven P Schwendeman
    Department of Pharmaceutical Sciences, The University of Michigan, Ann Arbor 48109 1065, USA
    Crit Rev Ther Drug Carrier Syst 19:73-98. 2002
    ..Described here are recent advances in the stabilization of proteins encapsulated in PLGA delivery systems...
  18. ncbi 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH
    Peter Hoare
    Child and Family Mental Health Service, Royal Hospital for Sick Children, 3 Rillbank Terrace, Edinburgh EH9 1LL, UK
    Eur Child Adolesc Psychiatry 14:305-9. 2005
    ....
  19. ncbi Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial
    Jasjit S Ahluwalia
    Department of Preventive Medicine and Public Health, University of Kansas School of Medicine and Kansas Cancer Institute, Kansas City, KS 66160 7313, USA
    JAMA 288:468-74. 2002
    ..Few clinical trials for smoking cessation in African Americans have been conducted, despite a different profile of both smoking and quitting patterns...
  20. ncbi Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy
    Donna Palumbo
    Strong Neurology ADHD Medical Center, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642 8673, USA
    J Child Adolesc Psychopharmacol 14:185-94. 2004
    ....
  21. ncbi Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
    ..The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation...
  22. ncbi Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
    M J Brown
    Clinical Pharmacology Unit, University of Cambridge, UK
    Lancet 356:366-72. 2000
    ..We compared the effects of the calcium-channel blocker nifedipine once daily with the diuretic combination co-amilozide on cardiovascular mortality and morbidity in high-risk patients with hypertension...
  23. ncbi Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9-12 February 2006, Salzburg, Austria
    A Morales
    Centre for Urological Research, Queen s University, Kingston, Canada
    Aging Male 9:221-7. 2006
    ..Best results are seen in diabetic hypogonadal patients. The regimen of injectable testosterone undecanoate administration ideally fits recommendations regarding pharmacokinetics, efficacy and safety monitoring...
  24. ncbi Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems
    Ben J Boyd
    Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, Parkville, VIC 3052, Australia
    Int J Pharm 309:218-26. 2006
    ..The stability of the H(II) phase to likely in vivo breakdown products was also assessed...
  25. pmc Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
    David P McDonnell
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    BMC Psychiatry 10:45. 2010
    ..The authors conducted a series of parallel investigations into the possible reasons PDSS events occur...
  26. ncbi Order of magnitude differences between methods for maintaining physiological 17beta-oestradiol concentrations in ovariectomized rats
    Jakob O Strom
    Department of Clinical Chemistry, Institute of Clinical and Experimental Medicine, University Hospital, Linkoping, Sweden
    Scand J Clin Lab Invest 68:814-22. 2008
    ..Silastic capsules are conveniently manufactured and used and are superior to pellets and injections in reliably producing long-term 17beta-oestradiol concentrations within the physiological range...
  27. ncbi Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial
    Douglas E Jorenby
    University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, Wis 53711, USA
    JAMA 296:56-63. 2006
    ..Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine...
  28. ncbi Polymeric system for dual growth factor delivery
    T P Richardson
    Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA
    Nat Biotechnol 19:1029-34. 2001
    ..This is the first report of a vehicle capable of delivery of multiple angiogenic factors with distinct kinetics, and these results clearly indicate the importance of multiple growth factor action in tissue regeneration and engineering...
  29. ncbi Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia
    Lizheng Shi
    Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, Suite 1900, New Orleans, LA 70112, USA
    Psychiatr Serv 58:482-8. 2007
    ....
  30. ncbi Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD
    Nora D Volkow
    National Institute on Drug Abuse NIH, 6001 Executive Boulevard, Room 5274 MSC 9581, Bethesda, MD 20892, USA
    Am J Psychiatry 160:1909-18. 2003
    ..The authors evaluated variables that distinguish these two properties...
  31. ncbi Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults
    Margaret A Drehobl
    Scripps Clinic Clinical Research, San Diego, CA, USA
    Chest 128:2230-7. 2005
    ..Treatment with a single-dose antibiotic regimen may improve compliance with prescribed therapy. A novel microsphere formulation of azithromycin provides a single-dose regimen while maintaining tolerability...
  32. ncbi A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA
    J Clin Psychopharmacol 25:218-25. 2005
    ..We conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia. The relapse rate is high after treatment discontinuation...
  33. ncbi Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF
    Prakash C Deedwania
    Department of Veterans Affairs Medical Center, Fresno, Calif, USA
    Am Heart J 149:159-67. 2005
    ....
  34. ncbi An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
    John Lauriello
    Department of Psychiatry, University of New Mexico, Albuquerque, NM 87131 001, USA
    J Clin Psychiatry 69:790-9. 2008
    ..To examine the efficacy and tolerability of a new injectable formulation of olanzapine, olanzapine long-acting injection (LAI), relative to placebo for treatment of acutely ill patients with schizophrenia...
  35. ncbi Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia
    Eric K Gupta
    University of the Pacific Thomas J Long School of Pharmacy and Health Sciences, Stockton, California, USA
    Heart Dis 4:124-37. 2002
    ..In this review, we will use "extended-release" to refer to the FDA approved slowly dissolving niacin preparation and "sustained-release" to refer to the nutritional supplements (not FDA approved)...
  36. ncbi Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine?
    Corey B Toal
    Department of Pharmacology, University of Toronto and Bayer Inc, Toronto, Ontario, Canada
    J Cardiovasc Pharmacol 44:82-6. 2004
    ..001) longer than for the other formulations. This study suggests marked formulation-dependent pharmacokinetics, which may have important clinical implications...
  37. ncbi Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants
    G K Hulse
    Unit for Research and Education in Drugs and Alcohol, School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia
    Addict Biol 9:67-72. 2004
    ..4 g naltrexone implants. These extended periods of coverage will offer significant benefits for managing the heroin-dependent patient...
  38. ncbi Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia
    Samuel J Keith
    Department of Psychiatry, University of New Mexico, Albuquerque 87131 1161, USA
    Psychiatr Serv 55:997-1005. 2004
    ..This article provides practical advice to physicians on the characteristics of patients who would benefit from treatment with long-acting atypical antipsychotic agents and offers suggestions on how to initiate treatment...
  39. ncbi Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease
    Malcolm Johnson
    GlaxoSmithKline Research and Development, Greenford Road, Middlesex UB6 OHE, UK
    Proc Am Thorac Soc 1:200-6. 2004
    ..Corticosteroid/beta(2)-agonist combined activity may also overcome the reduced sensitivity to inhaled corticosteroids that has been reported in some patients with COPD...
  40. ncbi Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism
    Lindsey Harle
    University of Texas, Medical Branch at Galveston, TX, USA
    Expert Opin Pharmacother 6:1751-9. 2005
    ..In this paper, the structure, pharmacokinetics, efficacy and side-effect profile of testosterone undecanoate will be reviewed and also compared with other existing testosterone esters...
  41. ncbi A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency
    Bernard L Silverman
    Department of Pediatrics, Northwestern University, Chicago, IL, USA
    J Pediatr Endocrinol Metab 15:715-22. 2002
    ..c.) injection. The availability of this formulation offers the opportunity for greater convenience and compliance by decreasing the number of injections and frequency of administration required...
  42. ncbi The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications
    J M Swanson
    Child Development Center, University of California, Department of Pediatrics, Irvine 92697 4480, USA
    J Atten Disord 6:S73-88. 2002
    ..In addition to efficacy, applications of the LSP to measure common side effects related to eating and sleeping were described and discussed...
  43. ncbi Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy
    Mellar P Davis
    The Harry R Horvitz Center for Palliative Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland OH 44195, USA
    Support Care Cancer 11:84-92. 2003
    ..Oxycodone's kappa receptor binding has little role in abuse or addiction. The cost of CR oxycodone is prohibitive for most American hospices...
  44. ncbi Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
    Allen J Taylor
    Cardiovascular Research, Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Ave, NW, Bldg 2, Room 3L28, Washington, DC 20307 5001, USA
    Circulation 110:3512-7. 2004
    ..Niacin reduces coronary heart disease morbidity and mortality when taken either alone or in combination with statins; however, the incremental impact of adding niacin to background statin therapy is unknown...
  45. ncbi Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?
    Thomas J Spencer
    Massachusetts General Hospital, Boston, 02114, USA
    J Am Acad Child Adolesc Psychiatry 45:527-37. 2006
    ..To investigate whether prolonged therapy with a long-acting stimulant affects growth in children with attention-deficit/hyperactivity disorder (ADHD)...
  46. ncbi Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, YAW 6 6A, 32 Fruit Street, Boston, MA 02114, USA
    Arch Pediatr Adolesc Med 160:82-90. 2006
    ..Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into adolescence, little is known about the efficacy and tolerability of stimulant medications in this age group...
  47. ncbi Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido)
    Aksam A Yassin
    Clinic of Urology Andrology, Segeberger Kliniken, Norderstedt Hamburg, Germany
    World J Urol 24:639-44. 2006
    ..So, these results argue for determination of T levels in elderly men with sexual problems. If the levels are subnormal, T treatment is warranted...
  48. ncbi Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs
    Kathy W Y Lee
    Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University Parkville Campus, 381 Royal Parade, Parkville, Victoria 3052, Australia
    Int J Pharm 365:190-9. 2009
    ....
  49. ncbi Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain
    Sharon M Weinstein
    MD Anderson Cancer Center, University o f Texas, Houston, Texas, USA
    Clin Ther 28:86-98. 2006
    ..Hydromorphone hydrochloride is a mu-opioid agonist with dose-dependent analgesic properties. Extended-release hydromorphone hydrochloride (ER hydromorphone HCl) capsules have been developed for administration every 24 hours...
  50. ncbi Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
    John F Paolini
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 101:625-30. 2008
    ..LRPT plus ERN was well tolerated. In conclusion, the significant reduction in ERN-induced flushing provided by LRPT plus ERN supports an accelerated ERN dose-advancement paradigm to achieve rapidly a 2-g dose in dyslipidemic patients...
  51. ncbi Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects
    Patrick Lemoine
    The Clinique Lyon Lumière, Meyzieu, France
    J Sleep Res 16:372-80. 2007
    ....
  52. ncbi Branch retinal artery occlusion after injection of a long-acting risperidone preparation
    Johnny Tang
    Ann Intern Med 147:283-4. 2007
  53. ncbi Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation
    E A Cefali
    Kos Pharmaceuticals, Inc, Cranbury, NJ, USA
    Int J Clin Pharmacol Ther 44:633-40. 2006
    ....
  54. ncbi Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes
    Wen Jiun Chou
    Department of Child Psychiatry, Chang Gung Memorial Hospital Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    Psychiatry Clin Neurosci 63:167-75. 2009
    ....
  55. pmc Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate
    Ahmed A Othman
    Pharmacokinetics Biopharmaceutics Laboratory, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
    AAPS J 9:E208-18. 2007
    ..The model performed well in simulation and leverage analysis indicated its robustness. The model will be a useful tool for future simulation studies...
  56. ncbi Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)
    J Siepmann
    College of Pharmacy, Universite d Angers, 16 Boulevard Daviers, 49100, Angers, France
    Adv Drug Deliv Rev 48:139-57. 2001
    ..The present article is a comprehensive review of the current state of the art of mathematical modeling drug release from HPMC-based delivery systems and discusses the crucial points of the most important theories...
  57. ncbi Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study
    Nathan Herrmann
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario, Canada
    Drugs Aging 26:403-7. 2009
    ..To determine if choice of drug and ease of administration affect persistence of therapy with cholinesterase inhibitors (ChEIs) for treatment of dementia...
  58. ncbi Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
    Renato Cozzi
    Division of Endocrinology, Ospedale Niguarda, Viale Ezio 5, I 20149 Milan, Italy
    J Clin Endocrinol Metab 91:1397-403. 2006
    ..Neurosurgery is regarded as the first-line treatment of acromegaly. Because of its low cure rate in macro and invasive adenoma, the role of primary medical treatment is debated...
  59. pmc Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148
    Michael P Dube
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Antivir Ther 11:1081-9. 2006
    ..Dyslipidaemia is very common in patients with HIV infection, but current therapies are often suboptimal. Since niacin may cause insulin resistance and hepatotoxicity, it has generally been avoided in this setting...
  60. ncbi Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics
    Larry Ereshefsky
    Department of Pharmacology, University of Texas Health Science Center at San Antonio and Clinical Research Unit, San Antonio State Hospital, 78229, USA
    J Clin Psychiatry 64:18-23. 2003
    ..Consistent with other long-acting medications, plasma drug level fluctuation is reduced more with long-acting than with oral risperidone. Analyses are currently underway to further examine safety outcomes with long-acting risperidone...
  61. ncbi Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline
    Tobias Banaschewski
    Dept of Child and Adolescent Psychiatry Psychotherapy, University of Goettingen, Von Siebold Str 5, 37075 Goettingen, Germany
    Eur Child Adolesc Psychiatry 15:476-95. 2006
    ..Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made...
  62. pmc Biodegradable nanoparticles for cytosolic delivery of therapeutics
    Jaspreet K Vasir
    Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Adv Drug Deliv Rev 59:718-28. 2007
    ....
  63. ncbi The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Curr Med Res Opin 22:2243-50. 2006
    ..Whether longer treatment with ERN would have a greater effect on carotid intima-media thickness (CIMT) is unknown...
  64. ncbi Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD
    Andrea Rossi
    Respiratory Division, Bergamo General Hospital, Bergamo, Italy
    Chest 121:1058-69. 2002
    ..To compare the efficacy, tolerability, and safety of therapy with formoterol and oral slow-release theophylline (THEO) in patients with COPD...
  65. ncbi Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
    Hans Jurgen Moller
    Department of Psychiatry, University of Munich, Germany
    Int Clin Psychopharmacol 20:121-30. 2005
    ..Direct initiation of RLAI was effective and well tolerated. RLAI provides an advancement in the treatment options available for a wide range of patients requiring long-term antipsychotic therapy...
  66. ncbi A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder
    Margaret Steele
    Department of Psychiatry, Pediatrics and Family Medicine, University of Western Ontario, London, ON
    Can J Clin Pharmacol 13:e50-62. 2006
    ..However, the most useful information to clinicians comes from an effectiveness study design...
  67. ncbi Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care
    O S Niaz
    Sheffield Care Trust, Sheffield
    Acta Psychiatr Scand 116:36-46. 2007
    ..To report the use of risperidone long-acting injection (RLAI) in a UK psychiatric service...
  68. ncbi Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol
    Gregg C Fonarow
    Ahmanson UCLA Cardiomyopathy Center, 10833 LeConte Avenue, Los Angeles, CA 90095 1679, USA
    Expert Opin Pharmacother 7:2533-46. 2006
    ....
  69. ncbi Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone
    Shelly Tadger
    Abarbanel Mental Health Center, Bat Yam and Sackler School of Medicine, Tel Aviv University, Israel
    Int Psychogeriatr 20:1245-50. 2008
    ..In elderly schizophrenia patients remission is difficult to determine due to long disease duration, exposure to differing treatments, long-standing side-effects, non-adherence, cognitive decline and physical comorbidity...
  70. ncbi Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination
    Vasilios Papademetriou
    Hypertension Research, VA Medical Center and Georgetown University Medical Center, Washington, DC 20422, USA
    Am J Hypertens 19:1217-25. 2006
    ..Thiazide diuretic/beta-blocker regimens lower BP, and clinical studies indicate that they reduce the risk for cardiovascular consequences of hypertension. Fixed-dose combination tablets can simplify multidrug treatment regimens...
  71. ncbi Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
    Michael A Kamm
    Department of Gastroenterology, St Mark s Hospital, Watford Road, Harrow, United Kingdom
    Gastroenterology 132:66-75; quiz 432-3. 2007
    ..A delayed-release oral mesalamine (ASACOL; Procter & Gamble, Cincinnati, OH) reference arm was included...
  72. ncbi Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid
    Susan M Schima
    Department of Medicine, Division of Cardiology, Creighton University School of Medicine, Omaha, NE 68131, USA
    Expert Opin Pharmacother 11:731-8. 2010
    ....
  73. ncbi Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe
    U W Tunn
    Urological Department, Städtisches Klinikum, Offenbach, Germany
    Prostate Cancer Prostatic Dis 12:83-7. 2009
    ..25 mg leuprorelin acetate in the treatment of prostate cancer...
  74. ncbi New for old? Risperidone long-acting injection in older patients
    Pamela Hudson-Jessop
    Nambour Hospital, Nambour, QLD, Australia
    Australas Psychiatry 15:461-4. 2007
    ..To describe six older patients who were treated with risperidone long-acting injection, and to discuss the role of this medication in a psychogeriatric setting...
  75. ncbi Depot risperidone in elderly patients: the experience of an Australian aged psychiatry service
    Dhiren Singh
    Int Psychogeriatr 19:789-92. 2007
  76. ncbi Synthesis of chemically cross-linked hydroxypropyl methyl cellulose hydrogels and their application in controlled release of 5-amino salicylic acid
    Soodabeh Davaran
    Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Science, Tabriz, Iran
    Drug Dev Ind Pharm 33:881-7. 2007
    ..5% to 2%. 5-Aminosalicylic acid (5-ASA) was used as a model of an anti-inflammatory drug. Cross-linked HPMC hydrogels were found to be a promising drug delivery system for the drugs to be delivered to the colon...
  77. ncbi Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes
    Alan G Wade
    CPS Research, Glasgow, UK
    Curr Med Res Opin 23:2597-605. 2007
    ..The efficacy and safety of a prolonged release melatonin formulation (PR-melatonin; Circadin* 2 mg) were examined in insomnia patients aged 55 years and older...
  78. ncbi Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia
    Roopal B Thakkar
    Abbott Laboratories, Abbott Park, Illinois 60064 6193, USA
    Am J Cardiovasc Drugs 9:69-79. 2009
    ..Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia. However, some patients discontinue NER treatment because of flushing, the most common adverse event associated with niacin therapy...
  79. ncbi Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD
    Yeni Kim
    Department of Psychiatry, Division of Child and Adolescent Psychiatry, Institute of Human Behavioral Medicine, Seoul National University Hospital, Seoul, Korea
    Hum Psychopharmacol 24:95-102. 2009
    ..This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH-IR) to osmotic release oral system methylphenidate (OROS-MPH)...
  80. ncbi Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol
    Linda S Henderson
    GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA
    J Clin Pharmacol 47:1358-65. 2007
    ..Ethanol did not alter the pharmacokinetic profile of carvedilol controlled-release...
  81. ncbi Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1
    E Lai
    Department of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey, USA
    Clin Pharmacol Ther 81:849-57. 2007
    ..In conclusion, the DP1 receptor antagonist laropiprant was effective in suppressing both subjective and objective manifestations of niacin-induced vasodilation...
  82. ncbi Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation
    E A Cefali
    Kos Pharmaceuticals, Inc, Cranbury, NJ, USA
    Int J Clin Pharmacol Ther 45:78-88. 2007
    ..The current study was designed to evaluate the effect of aspirin on various indices of flushing when administered with the optimized niacin ER formulation...
  83. ncbi Buprenorphine in long-term control of chronic pain in cancer patients
    Maria Caterina Pace
    Department of Anesthesiology, Surgical and Emergency Sciences, Second University of Naples, Naples, Italy
    Front Biosci 12:1291-9. 2007
    ..01), mental health (P = 0.03) and vitality (P = 0.001). These data indicated that the BT group showed an improvement of pain and a positive effect on the quality life...
  84. ncbi Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai Medical Center, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 165:721-30. 2008
    ....
  85. ncbi Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats
    Efstathios Karathanasis
    Department of Chemical Engineering, University of Houston, Houston, Texas, USA
    J Control Release 113:117-27. 2006
    ..Euglycemic clamp studies verified the accelerated insulin release upon application of cysteine...
  86. ncbi Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials
    Rudolf Likar
    Pain Clinic, General Hospital Klagenfurt, Klagenfurt, Austria, and Pain Clinic, University of Erlangen Nurnberg, Germany
    Clin Ther 28:943-52. 2006
    ..Long-term data are essential to determining the performance of an analgesic in the management of chronic pain...
  87. ncbi Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha
    S P Vyas
    Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Hari Singh Gour Vishwavidyalaya Sagar, MP, India
    Drug Dev Ind Pharm 32:699-707. 2006
    ..The results confirmed the possibility of multivesicular liposomes as a long-acting or sustained-release delivery system using a combination of pegylation and encapsulation technique for controlled delivery of interferon alpha...
  88. ncbi Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder
    Daniel J Cox
    Department of Psychiatric Medicine, University of Virginia, Charlottesville, Virginia, USA
    Pediatrics 118:e704-10. 2006
    ..Studies have demonstrated that stimulants improve driving performance. This study compared 2 long-acting stimulant medications during daytime and evening driving evaluations...
  89. ncbi Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)
    Christie M Ballantyne
    Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
    Am J Cardiol 101:1428-36. 2008
    ..In conclusion, this study showed that NER/S provided additional clinically relevant improvements in multiple lipid parameters and was safe and well tolerated...
  90. doi In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting
    Marilyn Martinez
    US Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drug Evaluation, Rockville, Maryland 20855, USA
    J Control Release 129:79-87. 2008
  91. ncbi Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia
    Raymond Rackley
    Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
    Urology 67:731-6; discussion 736. 2006
    ..To evaluate the efficacy and tolerability of nighttime tolterodine dosing on urgency-related micturitions in patients with overactive bladder (OAB) and nocturia...
  92. ncbi Extended-release intramuscular naltrexone
    Tracy Swainston Harrison
    Adis International Limited, Auckland, New Zealand
    Drugs 66:1741-51. 2006
    ..The proportion of patients with clinically significant plasma transaminase elevations was not different between patients receiving extended-release intramuscular naltrexone and those receiving placebo...
  93. pmc Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins
    Stefania Lamon-Fava
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA
    Arterioscler Thromb Vasc Biol 28:1672-8. 2008
    ..Extended-release niacin effectively lowers plasma TG levels and raises plasma high-density lipoprotein (HDL) cholesterol levels, but the mechanisms responsible for these effects are unclear...
  94. ncbi Extended treatment with bupropion SR for cigarette smoking cessation
    Joel D Killen
    Stanford University School of Medicine, Stanford, CA 94305 5705, USA
    J Consult Clin Psychol 74:286-94. 2006
    ..001; week 25: 48% vs. 31%, p = .001; week 52: 39% vs. 27%, p = .01). Because most smokers suffer relapse with any current cessation treatment, the comparatively high abstinence percentages achieved in this trial are of interest...
  95. ncbi Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
    Richard H Karas
    Division of Cardiology, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA
    Am J Cardiovasc Drugs 8:69-81. 2008
    ..This fact has focused increased attention on treating abnormalities of non-high-density lipoprotein-cholesterol (non-HDL-C), HDL-C, and triglycerides in national guidelines and has intensified interest in combination therapy...
  96. ncbi Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects
    Gary Kay
    Washington Neuropsychological Institute, Washington, DC 20016, USA
    Eur Urol 50:317-26. 2006
    ..To investigate the effects of darifenacin controlled-release (CR) and oxybutynin extended-release (ER) on cognitive function (particularly memory) in older subjects...
  97. pmc Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial
    Sandra D Comer
    Division on Substance Abuse, New York State Psychiatric Institute, and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York 10032, USA
    Arch Gen Psychiatry 63:210-8. 2006
    ..Oral naltrexone can completely antagonize the effects produced by opioid agonists. However, poor compliance with naltrexone has been a major obstacle to the effective treatment of opioid dependence...
  98. ncbi Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study
    A Vogt
    Charite Universitatsmedizin Berlin, Germany
    Curr Med Res Opin 22:417-25. 2006
    ....
  99. ncbi First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II, University of Naples, Italy
    Clin Endocrinol (Oxf) 64:342-51. 2006
    ..The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor...
  100. ncbi Effect of methylphenidate formulation on treatment patterns and use of emergency room services
    Jason E Kemner
    Medical Science Liaison, Ortho Urology, McNeil Consumer and Specialty Products, Fort Washington, PA, USA
    Am J Health Syst Pharm 63:317-22. 2006
    ....
  101. ncbi Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release
    Yaxin Lu
    School of Pharmacy 32 mail box, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, Liaoning Province, PR China
    J Pharm Sci 96:3252-62. 2007
    ....

Research Grants76

  1. PILOT EXPLORATIONS OF ZINC EFFECTS IN ADHD
    L Arnold; Fiscal Year: 2007
    ..Outcome measures include parent/teacher-rated ADHD symptoms for phases 1&2, and amphetamine optimal dose for phase 3. Tissue zinc will be determined by 3 state-of-the-art assays. ..
  2. Dopamine Transporter Binding by PET in Adult ADHD
    Thomas Spencer; Fiscal Year: 2007
    ..qenetic risk factors, a) We hypothesize that DAT binding will be associated with the 480 allele of the 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene. ..
  3. AN ECOGENETIC STUDY OF ADHD
    Stephen Faraone; Fiscal Year: 2003
    ..Furthermore, no studies have used an ecogenetic approach to sharpen the accuracy of risk prediction. ..
  4. TESTING THE VALIDITY OF ADULT ATTENTION DEFICIT DISORDER
    Stephen Faraone; Fiscal Year: 2002
    ..Thus, if founded, we expect that the proposed work will lead to a program of research that can both clarify the nosological complexities of adult ADHD and clarify the nature of genes that are risk factors for the disorder. ..
  5. CONTROLLED STUDY OF METHYLPHENIDATE IN ADULTS WITH ADHD
    Thomas Spencer; Fiscal Year: 2002
    ..The auditory and visual continuous performance tasks and the Stroop test will be used to further assess treatment efficacy. A larger neuropsychological battery will be used to assess the long term effects of MPH treatment. ..
  6. Validating Novel Familial Phenotypes of Drug Abuse
    Stephen Faraone; Fiscal Year: 2007
    ..State of the art statistical techniques will be employed. ..
  7. Analysis of an ADHD Whole Genome Association Scan
    Stephen Faraone; Fiscal Year: 2007
    ..All genotype data generated by the GAIN whole genome association scan will be made available to the scientific community by GAIN as soon as the genotypes are completed. [unreadable] [unreadable] [unreadable]..
  8. International Multi-Center ADHD Genetics Project
    Stephen Faraone; Fiscal Year: 2007
    ..abstract_text> ..
  9. 2/5-The Psychiatric GWAS Consortium: Integrated & Coordinated GWAS Meta-Analyses
    Stephen Faraone; Fiscal Year: 2008
    ..Finally, the PGC proposes to abide as fully as possible with the NIH's GWAS data sharing policies and we provide a detailed data sharing plan and timetable. [unreadable] [unreadable] [unreadable]..
  10. Searching for ADHD Susceptibility Genes
    Stephen V Faraone; Fiscal Year: 2010
    ..That, in turn, should facilitate the search for newer, more effective treatments for the disorder. ..
  11. PREVENTION OF CIGARETTE SMOKING IN ADHD YOUTH
    Joseph Biederman; Fiscal Year: 2001
    ..Since there are estimated to be 3.5 million children with ADHD and 20% have been shown to be smokers, targeting this group could potentially impact 700,000 children and adolescents. ..
  12. Adult Outcome of Attention Deficit Hyperactivity Disorder
    Joseph Biederman; Fiscal Year: 2007
    ..For these reasons, we expect the proposed work to clarify the course and outcome of ADHD. ..
  13. Collaborative Pediatric Bipolar Disorder Conference
    Joseph Biederman; Fiscal Year: 2007
    ..While the proposed conference does not intend to solve all outstanding problems associated with pediatric bipolar disorder, it will provide a forum to begin formulating a solution. ..
  14. LONGITUDINAL FOLLOW UP OF ADHD GIRLS AND THEIR SIBLINGS
    Joseph Biederman; Fiscal Year: 2002
    ....
  15. Course of psychopathology in female youth: Analysis with extant longitudinal data
    Joseph Biederman; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  16. Urodynamic and Multiethnic Variability of Men Treated b*
    Steven Kaplan; Fiscal Year: 2005
    ..Baseline urodynamic parameters which may predict improved outcome after MIST 3. The success of various types of MIST in treating BPH in African - American, Hispanic and Caucasian men. ..
  17. Substance Abuse in ADHD Girls
    Timothy Wilens; Fiscal Year: 2006
    ..Thus, the research, approach, and goals of this R01 application are consistent with those underscored in the PA and by the Institute of Medicine as being of the highest research priority. ..
  18. Minimally Invasive Surgical Therapies Treatment Consort*
    Claus Roehrborn; Fiscal Year: 2005
    ..The MIST Study Group will be a blueprint for a technology assessment group applicable to other areas of urology and other medical or surgical subspecialties. ..
  19. Medication Management Decisions in Schizophrenia
    Mark Olfson; Fiscal Year: 2003
    ..The results will inform quality improvement programs by identifying key modifiable determinants of the quality of medication management in the community treatment of schizophrenia. ..
  20. Juvenile Bipolar Disorder and Substance Abuse
    Timothy E Wilens; Fiscal Year: 2010
    ..Since BPD is identifiable and treatable, findings from the four-year follow-up will provide valuable information to formulate prevention and early intervention strategies. ..
  21. LONG TERM DRUG ABUSE IN ADHD
    Timothy Wilens; Fiscal Year: 2002
    ..abstract_text> ..
  22. OPIATE ENDOCRINE INTERACTIONS--DEVELOPMENTAL ASPECTS
    THEODORE CICERO; Fiscal Year: 2003
    ..The proposed animal studies could establish whether gender differences exist and if these differences are based on inherent, first-order biological differences between the sexes. ..
  23. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2001
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  24. Molecular Genetics of Inattention in Australia
    THEODORE CICERO; Fiscal Year: 2009
    ..This will be at a marked cost savings due to the employment of existing well-characterized samples and the long history of collaborative studies between investigators from Australia and the United States. ..
  25. Biometric and Measured Genetic Research on Smoking
    Gary Swan; Fiscal Year: 2007
    ..Such knowledge will confer new insights about the etiology and progression of smoking and should improve the current understanding of smoking, which is still largely descriptive. ..
  26. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Gregg Fonarow; Fiscal Year: 2006
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  27. Eighth Nerve Stimulation for the Treatment of ADHD
    L Arnold; Fiscal Year: 2003
    ..We hypothesize that CMA stimulation will show a larger effect than simple rotary stimulation, significant compared to sham control. Sufficient sample size is assured by the Ohio State University's recruitment record. ..
  28. RUPP-PI
    Oscar Bukstein; Fiscal Year: 2006
    ..The expertise and experience at this RUPP-PI site also will be directed to train new investigators. In creating TASA, a collaborative group of 8 applicants forged the ability to work together. ..
  29. PHARMACOKINETICS OF NICOTINE IN TWINS
    Gary Swan; Fiscal Year: 2002
    ..Ultimately, this knowledge may lead to more informed and more finely targeted treatment of individuals who are either susceptible to nicotine addiction or are already addicted to this substance. ..
  30. BUPRENORPHINE ABUSE BY HUMANS--LABORATORY STUDIES
    Sandra Comer; Fiscal Year: 2002
    ....
  31. Controlled Study of SAMe vs.Escitalopram in Major Depressive Disorder
    Maurizio Fava; Fiscal Year: 2008
    ..Secondary aims are to assess the acute effects of SAMe or escitalopram vs. placebo on remission rates, quality of life, and psychosocial functioning. ..
  32. Impact of Smoking Cessation on Sleep
    Gary Swan; Fiscal Year: 2008
    ..The results of this project will be particularly important for the development of targeted treatment approaches designed to ameliorate sleep disruption as part of an overall smoking cessation strategy. ..
  33. Pelvic Floor Changes Before and After Birth
    REBECCA GLENN ROGERS; Fiscal Year: 2010
    ..This project will provide fundamental data to guide future decisions about labor interventions to prevent PF changes as well as data-based decisions regarding maternal request cesarean. ..
  34. MR SPECTROSCOPIC IMAGING DURING METHADONE MAINTENANCE
    Mark Pollack; Fiscal Year: 2002
    ....
  35. Improving Outcomes in Pharmacotherapy of Social Phobia
    Mark Pollack; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  36. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2003
    ....
  37. Treatment of Nicotine Dependence in Health Care Setting
    Gary Swan; Fiscal Year: 2009
    ....
  38. D-Cycloserine Enhancement of Exposure in Social Phobia
    Mark H Pollack; Fiscal Year: 2010
    ..This study addresses an important public health issue by assessing an intervention that may lead to a more efficient and effective application of empirically based psychosocial interventions for the treatment of SAD. ..
  39. Impact of Trauma of Terroist Attack on Bipolar Patients
    Mark Pollack; Fiscal Year: 2003
    ..abstract_text> ..
  40. ADHD Phenotype Network: Animal Model to Clinical Trial
    Floyd Sallee; Fiscal Year: 2004
    ..abstract_text> ..
  41. Sustained-Release Naltrexone for Opioid Dependence: Longitudinal Study in Humans
    Sandra D Comer; Fiscal Year: 2010
    ....
  42. TREATMENT REFRACTORY PANIC DISORDER
    Naomi Simon; Fiscal Year: 2004
    ..abstract_text> ..
  43. Development of an Inventory of Depressive Symptomatology
    AUGUSTUS RUSH; Fiscal Year: 2005
    ..g., anxiety, irritability) (IDS-C and SR) that are in the public domain for use with patients across the age spans seen in practice and in research. ..
  44. Home Base Treatment for Drug Use in Early Adolescents
    Oscar Bukstein; Fiscal Year: 2005
    ..These interventions are expected to improve not only substance abuse outcomes, but a range of impairments and symptoms associated with the DBDs and high risk for the early onset type of substance use disorder. ..
  45. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2005
    ..abstract_text> ..
  46. PAIN AND ANALGESIC RESPONSE--SEX AND HORMONE VARIATIONS
    Sandra Comer; Fiscal Year: 2002
    ..In addition, they will more carefully examine sex differences in analgesic response to butorphanol and morphine, two agonists with differing selectivities for mu and kappa opioid receptors. ..
  47. CVD RISK FACTORS AND BRAIN MORPHOLOGY IN NHLBI TWINS
    Gary Swan; Fiscal Year: 2001
    ....
  48. Predicting Response to Atomoxetine and Methlyphenidate
    Jeffrey Newcorn; Fiscal Year: 2009
    ..abstract_text> ..
  49. DAYTIME SLEEPINESS--PREVALENCE, CONSEQUENCES, AND RISKS
    Thomas Roth; Fiscal Year: 2003
    ..The important contribution of the present proposal is that it will be the first population-based study to use laboratory assessments, its consequences and risks to measure sleepiness. ..
  50. Beaumont Interstitial Cystitis Clinical Research Network
    Kenneth Peters; Fiscal Year: 2007
    ..Adverse events and complications will be monitored. Ancillary studies as agreed upon by the ICCRN will be carried out in conjunction with the clinical trial. ..
  51. RARbeta in Melanoma: Epigenetic Regulation by Nutrients
    Richard Niles; Fiscal Year: 2007
    ..Depending on results obtained, this investigation can be translated into nutritional studies with animal models of melanoma. [unreadable] [unreadable] [unreadable]..
  52. Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
    Mitchell Goldman; Fiscal Year: 2006
    ..abstract_text> ..
  53. SERTRALINE FOR ALCOHOL DEPENDENCE AND DEPRESSION
    Helen Pettinati; Fiscal Year: 2003
    ..Overall, this project will determine if combining pharmacotherapies results in a better response in comorbidly depressed alcoholics than either medication alone or placebo. ..
  54. MDR1 and Related Proteins during HIV PI Exposure
    David Greenblatt; Fiscal Year: 2005
    ..The findings will be of importance in understanding lipid disorders related to PIs as well as the kinetics of drugs used to treat HIV and related disorders. ..
  55. Interleukin10 Microsphere in Inflammatory Bowel Disease
    NEJAT EGILMEZ; Fiscal Year: 2002
    ..T & B Bioclone intends to pursue the clinical use of the IL-10 microsphere technology for therapy of IBD in collaboration with our collaborators at Brown University. ..
  56. CLINICAL INVESTIGATOR TRAINING ENHANCEMENT: CITE PROGRAM
    Kurt Kroenke; Fiscal Year: 2004
    ..abstract_text> ..
  57. FUNCTIONAL LOCI MODIFYING SLE RENAL DISEASE
    Eric Sobel; Fiscal Year: 2003
    ..abstract_text> ..
  58. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael E Thase; Fiscal Year: 2010
    ....
  59. A Spanish Adaptation of the ASI-Multimedia Version
    Stephen Butler; Fiscal Year: 2002
    ..Due to its reliability and low cost, we believe the ASI-MV could become the "Gold Standard" addictions assessment. Under such a circumstance, a Spanish adaptation would enjoy widespread use and profitability. ..
  60. SCALING THE REINFORCING VALUE OF CIGARETTE SMOKE
    Jed Rose; Fiscal Year: 2003
    ..The results will lead to a better understanding of the role of pharmacologic and sensory/behavioral cues in nicotine addiction and smoking cessation. ..
  61. Quality Life Among Youth with Craniofacial Conditions
    Donald Patrick; Fiscal Year: 2004
    ..S., and one in the United Kingdom. Adolescents and their parents will complete questionnaires at baseline, and gain at 1-2 year clinical follow-up. ..
  62. Self-Assembly of Dynamic, Functional Protein Matrices
    William Murphy; Fiscal Year: 2004
    ..abstract_text> ..
  63. Pharmacogenetic Investigation of Naltrexone
    Caryn Lerman; Fiscal Year: 2007
    ..The long-term objective of this research is to discover and develop new pharmacogenetic treatment models that can be readily translated to the clinical setting to individualize pharmacotherapy and maximize effectiveness. ..
  64. Quality of Life of Overweight Youth: Multicultural View
    Donald Patrick; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  65. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2008
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. [unreadable] [unreadable] [unreadable] [unreadable]..
  66. NAPS2 Continuation - Genome-Wide Association Study of Pancreatitis
    David C Whitcomb; Fiscal Year: 2010
    ..Knowledge of the genetic basis of pancreatitis will lead to new treatments, and help remove the stigma that chronic pancreatitis is only a disease of drunkards. ..
  67. MOLECULAR GENETICS OF HEREDITARY PANCREATITIS
    David Whitcomb; Fiscal Year: 2008
    ..The HP and familial pancreatitis studies are especially important because of the statistical power of family studies and the ability to detect modifier genes in a uniform background of susceptibility factors. ..
  68. BIOBEHAVIORAL LUNG CANCER PREVENTION PROGRAM
    Caryn Lerman; Fiscal Year: 2004
    ..The long-term objective is to provide information necessary to match smoking cessation treatments to individuals, based on their genetic predispositions. ..
  69. Hearing Loss and Quality of Life of Children and Youth
    Donald Patrick; Fiscal Year: 2009
    ....
  70. Bipolar Disorder in Pregnancy: Predictors of Morbidity
    DONALD NEWPORT; Fiscal Year: 2009
    ..Furthermore, the novel PK data will expand our understanding of prenatal drug metabolism, and the project will establish a cohort of children of women with BPD with detailed prospective prenatal histories. ..
  71. Functional tissue engineering of tendon
    Stavros Thomopoulos; Fiscal Year: 2003
    ..It is expected that a combination of structural and compositional design will be necessary to achieve the viscoelastic properties of normal tendon. ..
  72. Management of Chronic Pain in Rehabilitation Medicine
    Mark Jensen; Fiscal Year: 2006
    ..A Scientific Core will provide scientific direction, project coordination, data collection and management, statistical support, and shared scientific expertise. ..
  73. Stigma & Quality of Life of Youth w/Facial Differences
    Donald Patrick; Fiscal Year: 2005
    ..Participants for this study will be recruited from sites in Seattle, Chicago, and Chapel Hill, NC. ..